Antibody Engineering Banner

Antibody Engineering

Antibody therapies have been approved for the treatment of cancer, immune disorders, metabolic, cardiovascular, and infectious diseases.  PepTalk’s Antibody Engineering pipeline offers a forum for protein scientists who are working to discover and develop differentiated biotherapeutics for additional unmet medical needs quickly and efficiently.   These programs explore smarter and higher throughput screening methods, novel discovery platforms, strategies for dealing with challenging targets and modalities, creative engineering approaches for improving the precision and efficacy of therapeutic antibodies and the increasing role of machine learning and AI in discovery and engineering.  Join us to explore the important advances in this dynamic field.

January 13

Symposium: Bispecific Engineering & Therapeutics

January 14-15

Training Seminar: Introduction to Antibody Engineering

January 15-16

Training Seminar: Antibody Drug Discovery: From Target to Lead


KEYNOTE PRESENTATION:

Hitoshi KatadaDirected Assembly of Bispecific Antibody by Electrostatic Steering—Development of Platform and Application to Therapeutic Antibodies
Hitoshi Katada, PhD, Head of Biologics Engineering, Research Division, Chugai Pharmaceutical Co. Ltd.



If you are working in the following areas join the PepTalk community: 

  • Antibody Discovery
  • Antibody Engineering
  • Antibody Technologies
  • Biologics Development
  • Biotherapeutics Development
  • Cellular Engineering
  • Development
  • Protein Engineering
  • Protein Sciences
  • Regulatory Affairs
  • Research
  • Translational Sciences